Pharma & Biotech

China’s CDE released guidelines on clinical trials of locally applied, locally acting products to improve drug development and evaluation

The China GMP for Pharmaceutical Packaging guides pharmaceutical marketing license holders in reviewing packaging material suppliers.

NMPA solicits comments on the revised draft of China's medical device classification for sodium hyaluronate products until June 16, 2022.

China NMPA regulations supporting Good Manufacturing Practice (GMP) of drugs in clinical trials will be implemented on July 1, 2022

The 14th Five-Year Plan for Drug Supervision Network Security and Information Construction issued by the NMPA will focus on 16 missions

Measures for the Supervision and Administration of Drug Production was issued by the SAMR and came into effect on July 1, 2020.

Measures for the Administration of Drug Registration took effect on July 1, 2020, to reform the drug review and approval system.

The Guideline for Pharmacovigilance Inspection urge MAHs to implement the main responsibility of pharmacovigilance.

China Drug Annual Reports Administrative Regulations was issued by the National Medical Products Administration on April 12, 2022.

Importing drugs and medical devices from Hong Kong have been approved and amounted up to 15 products into the GBA as of March 2022.

Clinical trials GMP management specification first issued its draft in July 2018. The appendix draft was issued on January 18, 2022.

Acceptance and examination of chemical APIs trial guidelines have had its first draft issued in April 2020.